Sequus Pharmaceuticals
CompanyUnited States
Sequus Pharmaceuticals develops one asset, in phase 3 (doxorubicin hydrochloride (liposomal) in breast cancer). Mostly small molecule acting on DNA damage response, apoptosis and TOP2B; based in the United States.
- Assets
- 1
- Furthest
- Phase 3
- Trials
- 4
- Signals
- 0
Pipeline
1doxorubicin hydrochloride (liposomal)
Topoisomerase II inhibitor and DNA intercalator formulated as an inhalation solution.
Phase 3Small moleculeDNA damage responseApoptosisbreast cancerHIV infection
Full company profiles: pipeline, trials, funding and people.
See Pro- Evidence behind the mechanisms4
- Trials5
- Signals1
- Similar companies6
Updated 7 Oct 2026 · 21 sources